Protein & Cell Biology
Cell-based potency & bioassay services
Relative potency testing for biologics and biosimilars, run as validated cell-based assays with tiered sample packages. Custom assay development available for other molecules.
Featured assays
Common biologics & biosimilars we test
Adalimumab
TNF-α neutralization assay| Package 1 · 1 sample | Rs. 810,000 |
| Package 2 · 2 samples | Rs. 815,000 |
| Package 3 · 3 samples | Rs. 1,100,000 |
Trastuzumab
BT-474 anti-proliferation assay| Package 1 · 1 sample | Rs. 805,000 |
| Package 2 · 2 samples | Rs. 810,000 |
| Package 3 · 3 samples | Rs. 1,090,000 |
Rituximab
Complement dependent cytotoxicity (CDC)| Package 1 · 1 sample | Rs. 1,575,000 |
| Package 2 · 2 samples | Rs. 1,600,000 |
| Package 3 · 3 samples | Rs. 2,135,000 |
Bevacizumab
VEGF neutralization assay| Package 1 · 1 sample | Rs. 825,000 |
| Package 2 · 2 samples | Rs. 830,000 |
| Package 3 · 3 samples | Rs. 1,111,000 |
The Database
Biologics potency assay database
60 innovator/biosimilar drug classes across 9 therapeutic groups. Reference cell lines are generic/brand-agnostic, listed only where a validated line is available — most classes are run as custom cell-based potency assays.
Drug class
Innovator (reference product)
Approved biosimilars
Test method & generic cell line
TNF-alpha Inhibitors
Inflammatory mAbs
Infliximab (Remicade)
Inflectra, Renflexis, Avsola, Remsima
TNF-alpha neutralization potency (cell-based reporter assay)
TNF-alpha Inhibitors
Inflammatory mAbs
Adalimumab (Humira)
Amjevita, Cyltezo, Hyrimoz, Hadlima, Hulio, Idacio, Yuflyma
TNF-alpha neutralization potency (cell-based reporter assay)
TNF-alpha Inhibitors
Inflammatory mAbs
Etanercept (Enbrel)
Erelzi, Eticovo
TNF-alpha neutralization potency (cell-based reporter assay)
TNF-alpha Inhibitors
Inflammatory mAbs
Golimumab (Simponi)
—
TNF-alpha neutralization potency (cell-based reporter assay)
TNF-alpha Inhibitors
Inflammatory mAbs
Certolizumab pegol (Cimzia)
—
TNF-alpha neutralization potency (cell-based reporter assay)
Anti-CD20 mAb
Oncology mAbs
Rituximab (Rituxan / MabThera)
Truxima, Ruxience, Riabni, Blitzima, Reditux
CD20 target binding + complement-dependent cytotoxicity (CDC) potencyCHO-K1/CD20 (Cat. M00916)
Anti-CD20 mAb
Oncology mAbs
Ofatumumab (Arzerra / Kesimpta)
—
CD20 target binding + CDC potencyCHO-K1/CD20 (Cat. M00916)
Anti-CD20 mAb
Oncology mAbs
Obinutuzumab (Gazyva)
—
CD20 target binding + ADCC potencyCHO-K1/CD20 (Cat. M00916)
Anti-HER2 mAb
Oncology mAbs
Trastuzumab (Herceptin)
Ogivri, Herzuma, Ontruzant, Trazimera, Kanjinti, Hercessi
HER2 target binding + ADCC/ADCP potency
Anti-HER2 mAb
Oncology mAbs
Pertuzumab (Perjeta)
—
HER2 target binding + ADCC potency
Anti-HER2 mAb
Oncology mAbs
Margetuximab (Margenza)
—
HER2 target binding + Fc-engineered ADCC potency
Anti-EGFR mAb
Oncology mAbs
Cetuximab (Erbitux)
—
EGFR target binding + ADCC potency
Anti-EGFR mAb
Oncology mAbs
Panitumumab (Vectibix)
—
EGFR target binding + ADCC potency
Anti-EGFR mAb
Oncology mAbs
Necitumumab (Portrazza)
—
EGFR target binding + ADCC potency
Anti-VEGF Biologics
Oncology mAbs
Bevacizumab (Avastin)
Mvasi, Zirabev, Alymsys, Vegzelma
VEGF neutralization potencyCHO-K1/VEGFR2 (Cat. M00906)
Anti-VEGF Biologics
Oncology mAbs
Ranibizumab (Lucentis)
Byooviz, Cimerli, Razumab
VEGF neutralization potencyCHO-K1/VEGFR2 (Cat. M00906)
Anti-VEGF Biologics
Oncology mAbs
Aflibercept (Eylea)
Yesafili, Opuviz
VEGF-trap neutralization potencyCHO-K1/VEGFR2 (Cat. M00906)
RANKL Inhibitor
Inflammatory mAbs
Denosumab (Prolia / Xgeva)
Jubbonti, Wyost, Osenvelt, Conexxence, Stoboclo
RANKL neutralization potency
IL-12 / IL-23 Inhibitors
Inflammatory mAbs
Ustekinumab (Stelara)
Wezlana, Selarsdi, Pyzchiva, Steqeyma, Otulfi
IL-12 and IL-23 signaling neutralization potency (dual pathway)
IL-23 Inhibitors
Inflammatory mAbs
Risankizumab (Skyrizi)
—
IL-23 signaling neutralization potency
IL-23 Inhibitors
Inflammatory mAbs
Guselkumab (Tremfya)
—
IL-23 signaling neutralization potency
IL-23 Inhibitors
Inflammatory mAbs
Tildrakizumab (Ilumya)
—
IL-23 signaling neutralization potency
IL-23 Inhibitors
Inflammatory mAbs
Mirikizumab (Omvoh)
—
IL-23 signaling neutralization potency
IL-6 / IL-6R Inhibitors
Inflammatory mAbs
Tocilizumab (Actemra)
Tyenne, Tofidence
IL-6 signaling neutralization potency
IL-6 / IL-6R Inhibitors
Inflammatory mAbs
Sarilumab (Kevzara)
—
IL-6R signaling neutralization potency
IL-6 / IL-6R Inhibitors
Inflammatory mAbs
Siltuximab (Sylvant)
—
IL-6 neutralization potency
IL-2 Agents
Immuno-oncology
Aldesleukin (Proleukin)
—
IL-2 bioactivity potency
Type I Interferons
Inflammatory mAbs
Interferon beta-1a (Avonex / Rebif)
—
Type I IFN bioactivity potency
Type I Interferons
Inflammatory mAbs
Interferon beta-1b (Betaseron / Extavia)
—
Type I IFN bioactivity potency
Type I Interferons
Inflammatory mAbs
Peginterferon beta-1a (Plegridy)
—
Type I IFN bioactivity potency
G-CSF Agents
Hematology Support
Filgrastim (Neupogen)
Zarxio, Nivestym, Releuko
G-CSF bioactivity potency
G-CSF Agents
Hematology Support
Pegfilgrastim (Neulasta)
Fulphila, Udenyca, Ziextenzo, Nyvepria
G-CSF bioactivity potency (sustained-release)
GM-CSF Agents
Hematology Support
Sargramostim (Leukine)
—
GM-CSF bioactivity potency
hCG
Metabolic / Hormone
Choriogonadotropin alfa (Ovitrelle / Ovidrel)
—
hCG bioactivity potency
Insulin & Analogs
Metabolic / Hormone
Insulin glargine (Lantus)
Basaglar, Semglee
Insulin receptor activation potencyHEK293/Luc/INSR (Cat. M01134)
Insulin & Analogs
Metabolic / Hormone
Insulin aspart (NovoLog)
Kirsty
Insulin receptor activation potencyHEK293/Luc/INSR (Cat. M01134)
Insulin & Analogs
Metabolic / Hormone
Insulin lispro (Humalog)
Admelog
Insulin receptor activation potencyHEK293/Luc/INSR (Cat. M01134)
Insulin & Analogs
Metabolic / Hormone
Insulin degludec (Tresiba)
—
Insulin receptor activation potencyHEK293/Luc/INSR (Cat. M01134)
GLP-1 Receptor Agonists
Metabolic / Hormone
Semaglutide (Ozempic / Wegovy)
—
GLP-1R pathway activation potencyHEK293/CRE-Luc/GLP1R (M00562) or CHO-K1/GLP1R/G-alpha15 (M00451)
GLP-1 Receptor Agonists
Metabolic / Hormone
Liraglutide (Victoza / Saxenda)
—
GLP-1R pathway activation potencyHEK293/CRE-Luc/GLP1R (Cat. M00562)
GLP-1 Receptor Agonists
Metabolic / Hormone
Dulaglutide (Trulicity)
—
GLP-1R pathway activation potencyHEK293/CRE-Luc/GLP1R (Cat. M00562)
GIP / GLP-1 Dual Co-Agonists
Metabolic / Hormone
Tirzepatide (Mounjaro / Zepbound)
—
Dual GLP-1R + GIPR pathway activation potency (both receptor lines required)GLP-1R: M00562/M00451; GIPR: RD00938/M00486
PTH / PTHrP Analogs
Metabolic / Hormone
Teriparatide (Forteo)
—
PTH1R pathway activation potencyCHO-K1/PTH1/G-alpha15 (Cat. M00315)
PTH / PTHrP Analogs
Metabolic / Hormone
Abaloparatide (Tymlos)
—
PTH1R pathway activation potencyCHO-K1/PTH1/G-alpha15 (Cat. M00315)
Fc Effector Function (ADCC)
Platform / Effector Function
Any therapeutic IgG1 mAb
—
ADCC potency — FcyRIIIa/CD16a reporter assay (platform test, not molecule-specific)CHO-K1/CD16A 158V (Cat. M00597)
Fc Effector Function (ADCP)
Platform / Effector Function
Any therapeutic IgG mAb
—
ADCP potency — FcyRIIa/CD32a reporter assay (platform test, not molecule-specific)CHO-K1/CD32A 131H (Cat. M00598)
Complement Pathway Inhibitors
Complement System
Eculizumab (Soliris)
Bkemv, Epysqli
C3a/C5a functional quantification; classical & terminal pathway activity
Complement Pathway Inhibitors
Complement System
Ravulizumab (Ultomiris)
—
C3a/C5a functional quantification; classical pathway activity
Complement Pathway Inhibitors
Complement System
Pegcetacoplan (Empaveli)
—
C3a functional quantification; terminal pathway (MAC) activity
Complement Pathway Inhibitors
Complement System
Iptacopan (Fabhalta)
—
Alternative pathway functional activity
Complement Pathway Inhibitors
Complement System
Danicopan (Voydeya)
—
Alternative pathway functional activity
Complement Pathway Inhibitors
Complement System
Sutimlimab (Enjaymo)
—
Classical pathway functional activity
Complement Pathway Inhibitors
Complement System
Narsoplimab
—
Lectin (MBL) pathway functional activity
CD19 x CD3 T-cell Engager
Bispecific / T-cell Engager
Blinatumomab (Blincyto)
—
T-cell activation / bispecific potency (CD19 x CD3)
Anti-CD19 mAb
Bispecific / T-cell Engager
Tafasitamab (Monjuvi)
—
CD19 target binding + ADCC potency
BCMA x CD3 T-cell Engager
Bispecific / T-cell Engager
Teclistamab (Tecvayli)
—
T-cell activation / bispecific potency
AAV Gene Therapies
Gene Therapy
Onasemnogene abeparvovec (Zolgensma, AAV9)
—
Vector transduction efficiency / anti-AAV neutralizing antibody (NAb) detectionAAV9 packaging + responsive reporter line
AAV Gene Therapies
Gene Therapy
Voretigene neparvovec (Luxturna, AAV2)
—
Vector transduction efficiency / anti-AAV NAb detectionAAV2 packaging + responsive reporter line
AAV Gene Therapies
Gene Therapy
Etranacogene dezaparvovec (Hemgenix, AAV5)
—
Vector transduction efficiency / anti-AAV NAb detectionAAV5 packaging + responsive reporter line
AAV Gene Therapies
Gene Therapy
Valoctocogene roxaparvovec (Roctavian, AAV5)
—
Vector transduction efficiency / anti-AAV NAb detectionAAV5 packaging + responsive reporter line
Not all molecules are stock-held — confirm availability when requesting a quote.
Related
You might also need
Get in touch
Book a free consultation
Send us a brief overview of your project — our scientific team will review it and get back with a proposal.